Answer
Thrombotic microangiopathy and serious thrombotic events were reported in a clinical study in patients receiving Hemlibra (emicizumab) prophylaxis when an average cumulative aPCC dose exceeding 100 U/kg per 24 hours was administered for 24 hours or more.
Sources for this answer
- Hemlibra 30 mg/mL and 150 mg/mL Solution for InjectionRoche Products Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 17Document updated
Sources checked